DOCSLIB.ORG

Corporate Action Tracker

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Corporate Action Tracker Corporate Action Tracker st nd Corporate Action a nd Result Calendar May 21 – Jun 02 , 2018 Bonus Company Ratio Ex-Date G.M.Breweries 1:4 21-May-18 Coastal Corporation 3:1 23-May-18 Split Company Ratio Ex-Date Gaekwar Mills 100:10 31-May-18 Right N.A. Buyback Company Ex Date Start Date End Date Offer Price Smartlink Holdings 17-May-18 -- -- 120.00 Netlink Solutions (India) 18-May-18 -- -- 17.00 Open Offer Company Start Date End Date Offer Price Envair Electrodyne 11-May-18 25-May-18 32.50 Rajputana Investment and Finance 15-May-18 28-May-18 11.50 Econo Trade (India) 16-May-18 29-May-18 20.00 HK Trade International 17-May-18 30-May-18 20.00 Xchanging Solutions 18-May-18 31-May-18 55.22 Dividend for May 21st – Jun 02nd, 2018 Dividend Company Type (In Rs) Ex-Date Merck Dividend 15.00 21-May-18 Mold-Tek Technologies Interim Dividend 0.30 21-May-18 Mold-Tek Packaging Interim Dividend 2.00 21-May-18 Raymond Dividend 3.00 22-May-18 R Systems International Interim Dividend 0.60 22-May-18 Gateway Distriparks Interim Dividend 4.00 23-May-18 GHCL Dividend 5.00 23-May-18 DCB Bank Dividend 0.75 24-May-18 Ingersoll-Rand (India) Interim Dividend 202.00 24-May-18 Trident Final Dividend 0.30 24-May-18 ITC Dividend 5.15 25-May-18 Colgate-Palmolive (India) Interim Dividend -- 29-May-18 Manappuram Finance Interim Dividend 0.50 29-May-18 Suyog Telematics Interim Dividend 1.00 29-May-18 Oberoi Realty Dividend 2.00 31-May-18 Page Industries Interim Dividend -- 31-May-18 Responsive Industries Dividend 0.10 31-May-18 1 Corporate Action Result Calendar for May 21st – Jun 02nd, 2018 Date: 21-May-18 63 moons Technologies AstraZeneca Pharma India CCL Products (India) Colgate Palmolive (India) DLF Dhunseri Petrochem Dhunseri Tea & Industries Future Retail GSPL IL&FS Transportation IMFA Just Dial Mahanagar Gas Motilal Oswal Fin Services Navkar Corporation Petronet LNG Redington (India) Timken India TTK Prestige Date: 22-May-18 Andhra Bank Bata India Bharat Forge Bosch Capital Trust CARE Ratings Cipla Dr. Reddy's Laboratories Future Consumer HPCL Igarashi Motors IOC Jamna Auto Industries L&T Technology Services Music Broadcast Salasar Techno Eng State Bank of India Sonata Software Symphony VIP Industries Date: 23-May-18 Astral Poly Technik Atlas Cycles (Haryana) Bajaj Electricals CESC CL Educate Dhanlaxmi Bank eClerx Services ENIL Eros International Media Finolex Industries Godrej Industries Grasim Industries IFCI Indraprastha Gas Jet Airways Jain Irrigation Systems KPIT Technologies L&T Infotech Motherson Sumi Systems Natco Pharma Omaxe Ramco Cements Ramco Systems Repco Home Finance SCI Shalimar Paints SML Isuzu Sunteck Realty Tata Motors TD Power Systems Vinyl Chemicals (India) Welspun Investments Date: 24-May-18 Ajmera Realty Amrutanjan Health Care Camlin Fine Sciences CEBBCO Cochin Shipyard City Union Bank Cummins India LT Foods Dolphin Offshore GAIL (India) GlaxoSmithKline Pharma Granules India HeidelbergCement India Heritage Foods Jindal Drilling KSCL MOIL NCC Pidilite Industries Plastiblends India United Breweries United Spirits V-Mart Retail Zydus Wellness Date: 25-May-18 Bank of Baroda BEML Cadila Healthcare Cantabil Retail India Central Bank of India Dhunseri Investments Electrotherm (India) Engineers India Eris Lifesciences Excel Crop Care Future Enterprises FMNL GICRE Gujarat Sidhee Cement Gujarat Fluorochemicals Himatsingka Seide Hindustan Copper Hindustan Motors Hotel Leela Venture IDBI Bank The Indian Hotels Company The India Cements Indosolar Jagran Prakashan Jai Corp JB Chemicals Jindal Saw Kalpataru Power Karur Vysya Bank Lakshmi Vilas Bank Lakshmi Machine Works Lemon Tree Hotels Max Financial Services Monte Carlo Fashions NBCC (India) NLC India Orissamine Page Industries PC Jeweller PFC S H Kelkar and Company Shriram EPC Sundaram Finance Sun Pharmaceutical Tech Mahindra Thangamayil Jewellery VA Tech Wabag Zuari Global Date: 26-May-18 Alpa Laboratories Avanti Feeds Bajaj Hindusthan Sugar BF Investment Corporation Bank Divi's Laboratories Dixon Technologies Liberty Shoes National Aluminium Co Sandhar Technologies Seshasayee Paper and Boards Speciality Restaurants SSWL TFCI VRL Logistics Wonderla Holidays 2 Corporate Action Date: 28-May-18 Asian Hotels (North) Astra Microwave Aurobindo Pharma Bank of India Cox & Kings Dalmia Bharat Sugar D B Realty Dredging Corporation EIH Associated Hotels Emkay Global Fin Services Finolex Cables Insecticides (India) Indian Overseas Bank Intrasoft Technologies Kwality Lovable Lingerie Larsen & Toubro NHPC NMDC NTPC Oil India Prakash Constrowell Prestige Estates Projects REC Ltd Ruchi Soya Industries SJVN STC India Syncom Healthcare Uflex Venus Remedies Walchandnagar Industries Date: 29-May-18 Balmer Lawrie & Company BEL BHEL BPCL C&C Constructions Coal India Glenmark Pharmaceuticals IPCA Laboratories J.Kumar Infraprojects Mahindra & Mahindra Max India MMTC Power Grid Corporation Torrent Power TTK Healthcare Titagarh Wagons UFO Moviez India Unichem Laboratories Wheels India Date: 30-May-18 Aban Offshore Asian Hotels (West) Andhra Cements Apollo Hospitals Berger Paints BGR Energy Systems Binani Industries CG Power & Industrial Deepak Fertilizers EIH FACT MBL Infrastructures Mishra Dhatu Nigam MTNL Info Edge (India) Nitesh Estates Puravankara Rajesh Exports SAIL Tide Water Oil TNPL Torrent Pharmaceuticals V-Guard Industries Note: Selection Criteria: BSE 500 Companies. The data is subject to change owing to corporate announcements or rescheduling of board meetings by companies post releasing of the report. Board Meetings for May 21st – Jun 02nd, 2018 Company Meeting Date Purpose CMI 21-May-18 General Essar Shipping 21-May-18 General Just Dial 21-May-18 Employees Stock Option Plan Prabhat Telecoms (India) 21-May-18 Bonus Issue Andhra Bank 22-May-18 Fund Raising DCW 22-May-18 Right Issue of Equity Shares Indiabulls Housing Finance 23-May-18 Fund Raising Sunteck Realty 23-May-18 Fund Raising Camlin Fine Sciences 24-May-18 Fund Raising Kaveri Seed Company 24-May-18 Buy Back of Shares Continental Seeds and Chemicals 25-May-18 General Future Enterprises 25-May-18 Fund Raising General Insurance Corporation of India 25-May-18 Bonus Issue R Systems International 25-May-18 General The Western India Plywoods 26-May-18 Dividend NTPC 28-May-18 Dividend Lotus Eye Hospital and Institute 29-May-18 Dividend Aban Offshore 30-May-18 Fund Raising Vipul 30-May-18 Dividend 3 Corporate Action Other Company Ex Date Purpose Zandu Realty 24-May-18 Scheme of Amalgamation Research Analyst Registration No. Contact Website Email Id INH000002764 SMS: ‘Arihant’ to 56677 www.arihantcapital.com [email protected] Arihant is Forbes Asia’s ‘200 Best under a $Billion’ Company ‘Best Emerging Commodities Broker’ awarded by UTV Bloomberg Disclaimer: This document has been prepared by Arihant Capital Markets Limited (hereinafter called as Arihant) and its subsidiaries and associated companies. This document does not constitute an offer or solicitation for the purchase and sale of any financial instrument by Arihant. Receipt and review of this document constitutes your agreement not to circulate, redistribute, retransmit or disclose to others the contents, opinions, conclusion, or information contained herein. This document has been prepared and issued on the basis of publicly available information, internally developed data and other sources believed to be reliable. Whilst meticulous care has been taken to ensure that the facts stated are accurate and opinions given are fair and reasonable, neither the analyst nor any employee of our company is in any way is responsible for its contents and nor is its accuracy or completeness guaranteed. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. All recipients of this material should before dealing and or transacting in any of the products referred to in this material make their own investigation, seek appropriate professional advice. The investments discussed in this material may not be suitable for all investors. The recipient alone shall be fully responsible/are liable for any decision taken on the basis of this material. Arihant Capital Markets Ltd (including its affiliates) or its officers, directors, personnel and employees, including persons involved in the preparation or issuance of this material may; (a) from time to time, have positions in, and buy or sell or (b) be engaged in any other transaction and earn brokerage or other compensation in the financial instruments/products discussed herein or act as advisor or lender/borrower in respect of such securities/financial instruments/products or have other potential conflict of interest with respect to any recommendation and related information and opinions. The said persons may have acted upon and/or in a manner contradictory with the information contained here and may have a position or be otherwise interested in the investment referred to in this document before its publication. The user of this report assumes the entire risk of any use made of this data / Report. Arihant especially states that it has no financial liability, whatsoever, to the users of this Report . Arihant Capital Markets Ltd #1011, Solitaire Corporate Park, Building No.10, 1st Floor, Andheri Ghatkopar Link Road, Chakala, Andheri (E), Mumbai-400093 T. 022-42254800. Fax: 022-42254880 www.arihantcapital.com 4 .
Load more

Recommended publications
  • Inner 24 India Pharma & Healthcare Fund Low
    Tata India Pharma & Healthcare Fund (An open ended equity scheme investing in Pharma and Healthcare Services Sector) As on 30th June 2020 PORTFOLIO INVESTMENT STYLE Company name No. of Market Value % of Company name No. of Market Value % of Primarily focuses on investment in at least 80% of its net Shares Rs. Lakhs Assets Shares Rs. Lakhs Assets assets in equity/equity related instruments of the Equity & Equity Related Total 23733.48 98.49 companies in the Pharma & Healthcare sectors in India. Healthcare Services Other Equities^ 380.78 1.58 INVESTMENT OBJECTIVE Narayana Hrudayalaya Ltd. 382720 1025.69 4.26 Repo 871.61 3.62 The investment objective of the scheme is to seek long Healthcare Global Enterprises Ltd. term capital appreciation by investing atleast 80% of its 410000 503.48 2.09 Portfolio Total 24605.09 102.11 net assets in equity/equity related instruments of the Apollo Hospitals Enterprise Ltd. 32500 438.70 1.82 Net Current Liabilities -507.01 -2.11 companies in the pharma & healthcare sectors in Pharmaceuticals India.However, there is no assurance or guarantee that Net Assets 24098.08 100.00 the investment objective of the Scheme will be Sun Pharmaceutical Industries Ltd. 870100 4115.14 17.08 achieved.The Scheme does not assure or guarantee any Dr Reddys Laboratories Ltd. 98000 3866.05 16.04 returns. Divi Laboratories Ltd. 102500 2335.87 9.69 DATE OF ALLOTMENT Lupin Ltd. 223000 2033.31 8.44 December 28, 2015 Ipca Laboratories Ltd. 95000 1590.68 6.60 Cipla Ltd. 230000 1472.58 6.11 FUND MANAGER Aurobindo Pharma Ltd.
    [Show full text]
  • The Ramco Cements Limited Capacity Additions and Efficiencies to Drive Profitable Growth
    The Ramco Cements Limited Capacity additions and efficiencies to drive profitable growth Powered by the Sharekhan 3R Research Philosophy Cement Sharekhan code: RAMCOCEM Result Update Update Stock 3R MATRIX + = - Summary We maintain Buy The Ramco Cements Limited (Ramco) with a revised PT of Rs. 1,250, Right Sector (RS) ü factoring upwardly revised estimates and strong earnings growth outlook. In Q4FY2021, the company reported marginally lower-than-expected operational Right Quality (RQ) ü performance owing to clinker capacity constraints, while net earnings were lower on account of higher tax outgo. Right Valuation (RV) ü The commissioning of 3.75MT clinker capacities in FY2022 would ease clinker capacity constraints, aiding in capturing pent-up demand as COVID-led restrictions + Positive = Neutral - Negative are reversed. The company would unveil the next round of capacity expansion plans, balancing What has changed in 3R MATRIX leverage and growth opportunities. Old New For Q4FY2021, The Ramco Cements Limited (Ramco) reported marginally lower-than-expected operational performance, owing to clinker capacity constraints, while net earnings were lower on RS account of a higher effective tax rate (ETR). Standalone revenue rose by 17.3% y-o-y (up 21.8% q-o-q) to Rs. 1,631 crore, led by a 9.5% y-o-y rise in cement volumes, while blended realisations were up 7.5% y-o-y (almost flat q-o-q). The company witnessed a strong demand environment RQ during Q4FY2021, in line with the industry, which led to 92% utilisation rate based on clinker capacity for Q4FY2021 (March 2021 witnessing 100% utilisation based on clinker capacity).
    [Show full text]
  • Annual-Report-2018-1
    Index Corporate Overview 2-33 About NATCO Pharma 2 Key milestones 6 Business highlights FY 2018-19 8 Key performance indicators 10 Megatrends 12 Management message 14 Building businesses in diverse markets 18 Leveraging synergies through diversity 20 Advancing R&D diversification 22 Board of Directors and Key 24 Management Team Risk framework and mitigation 26 strategy Corporate social responsibility (CSR) 28 Environment, health & safety (EHS) 32 Key numbers of FY 2018-19 on consolidated basis Statutory Reports 34-98 Total Revenue PAT Management Discussion and Analysis 34 Board's Report 43 ` 22,247 million ` 6,444 million Corporate Governance Report 71 Business Responsibility Report 90 EBITDA Basic EPS ` 9,250 million ` 34.98 Financial Statements 99-192 Disclaimer Standalone Financials 99 In this Annual Report, we have disclosed forward-looking information to enable investors to comprehend our prospects and take investment decisions. This report and Consolidated Financials 147 other statements - written and oral - that we periodically make contain forward-looking statements that set out anticipated results based on the management’s plans and assumptions. We have tried, wherever possible, to identify such statements by using words such as ‘anticipate’, ‘estimate’, ‘expects’, ‘projects’, ‘intends’, ‘plans’, ‘believes’, and Notice 193 words of similar substance in connection with any discussion of future performance. We cannot guarantee that these forward-looking statements will be realised, although we believe we have been prudent in our assumptions. The achievements of results are subject to risks, uncertainties and even inaccurate assumptions. Should known or unknown risks or uncertainties materialise, or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected.
    [Show full text]
  • Natco Pharma Limited
    Placement Document Not for Circulation Private and Confidential Serial No. [●] NATCO PHARMA LIMITED Originally incorporated as Natco Fine Pharmaceuticals Private Limited on September 19, 1981, the name of our Company was changed to “Natco Pharma Limited” on December 30, 1994 under the Companies Act, 1956. The registered office of our Company is at Natco House, Road no. 2, Banjara Hills, Hyderabad – 500 034, Telangana; Telephone: +91 40 2354 7532; Fax: +91 40 2354 8243; Email: [email protected]; Website: www.natcopharma.co.in; Corporate identification number:L24230TG1981PLC003201. Natco Pharma Limited (our “Company” or the “Issuer”) is issuing 1,600,000 equity shares of face value of Rs. 10 each (the “Equity Shares”) at a price of Rs. 2,130.55 per Equity Share, including a premium of Rs. 2,120.55 per Equity Share, aggregating to Rs. 3,408.88 million (the “Issue”). ISSUE IN RELIANCE UPON SECTION 42 OF THE COMPANIES ACT, 2013, AS AMENDED, READ WITH RULES MADE THEREUNDER, AND CHAPTER VIII OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2009, AS AMENDED (THE “SEBI ICDR REGULATIONS”). THIS ISSUE AND THE DISTRIBUTION OF THIS PLACEMENT DOCUMENT IS BEING MADE TO QUALIFIED INSTITUTIONAL BUYERS (“QIBs”) AS DEFINED IN THE SEBI ICDR REGULATIONS IN RELIANCE UPON CHAPTER VIII OF THE SEBI ICDR REGULATIONS, AS AMENDED AND SECTION 42 OF THE COMPANIES ACT, 2013, AS AMENDED, AND RULES MADE THEREUNDER. THIS PLACEMENT DOCUMENT IS PERSONAL TO EACH PROSPECTIVE INVESTOR AND DOES NOT CONSTITUTE AN OFFER OR INVITATION OR SOLICITATION OF AN OFFER TO THE PUBLIC OR TO ANY OTHER PERSON OR CLASS OF INVESTORS WITHIN OR OUTSIDE INDIA OTHER THAN QIBs.
    [Show full text]
  • The Ramco Cements Estimate Change CMP: INR802 TP: INR750 (-6%) Neutral
    3 November 2020 2QFY21 Results Update | Sector: Cement The Ramco Cements Estimate change CMP: INR802 TP: INR750 (-6%) Neutral TP change Beneficiary of South production discipline Rating change Retain Neutral on valuation pricing in strong EPS growth Bloomberg TRCL IN The Ramco Cements’ (TRCL) 2QFY21 results highlight the benefits of high Equity Shares (m) 236 cement prices in South India, which led to the highest ever cement EBITDA/t M.Cap.(INRb)/(USDb) 189.1 / 2.5 at INR1,895 (+94% YoY). Volumes, however, declined 19% YoY due to weak 52-Week Range (INR) 883 / 457 cement demand in South India. 1, 6, 12 Rel. Per (%) 5/27/1 We raise our FY21/FY22E EPS by 26%/5%, factoring in a strong realization 12M Avg Val (INR M) 513 outlook on the back of a strong production discipline in South. However, we retain our Neutral rating on 12.7x FY22E EV/EBITDA pricing in growth. Financial Snapshot (INR bn) Y/E Mar 2020 2021E 2022E Strong realization leads to EBITDA beat despite weak volumes Sales 53.4 54.5 63.2 Revenue/EBITDA/PAT stood at -4%/+52%/+40% YoY to EBITDA 11.1 15.9 16.6 Adj. PAT 6.0 8.5 8.3 INR12.6b/INR4.4b/INR2.4b, v/s our estimate of -3%/ +28%/ +28%. The beat EBITDA Margin (%) 20.8 29.2 26.3 was led by higher-than-expected realization at INR5,558/t (est. INR5,514/t). Adj. EPS (INR) 25.5 35.9 35.0 Sales volumes declined 19% YoY to 2.21mt (v/s est.
    [Show full text]
  • Company Reliance Industries Limited Tata Consultancy Services
    Top 1000 Private Sector Companies (Rank-wise List) Company Reliance Industries Limited Tata Consultancy Services (TCS) Infosys Technologies Ltd Wipro Limited Bharti Tele-Ventures Limited ITC Limited Hindustan Lever Limited ICICI Bank Limited Housing Development Finance Corp. Ltd. TATA Steel Limited Ranbaxy Laboratories Limited HDFC Bank Ltd Tata Motors Limited Larsen & Toubro Limited (L&T) Satyam Computer Services Ltd. Maruti Udyog Limited Bajaj Auto Ltd. HCL Technologies Ltd. Hero Honda Motors Limited Hindalco Industries Ltd Reliance Energy Limited Grasim Industries Limited Jet Airways (India) Ltd. Sun Pharmaceuticals Industries Ltd Cipla Ltd. Gujarat Ambuja Cements Ltd. Videsh Sanchar Nigam Limited The Tata Power Company Limited Sterlite Industries (India) Ltd. Associated Cement Companies Ltd. Nestlé India Ltd. Hindustan Zinc Limited GlaxoSmithKline Pharmaceuticals Limited Siemens India Ltd. Motor Industries Company Limited Mahindra & Mahindra Limited UTI Bank Ltd. Zee Telefilms Limited Bharat Forge Limited ABB Limited i-Flex Solutions Ltd. Dr. Reddy's Laboratories Ltd. Nicholas Piramal India Limited Kotak Mahindra Bank Limited Reliance Capital Ltd. Ultra Tech Cement Ltd. Patni Computer Systems Ltd. Wockhardt Limited Indian Petrochemicals Corporation Limited Biocon India Limited Essar Oil Limited. Asian Paints Ltd. Dabur India Limited Jaiprakash Associates Limited JSW Steel Limited Tata Chemicals Limited Tata Tea Limited Tata Teleservices (Maharashtra) Limited The Indian Hotels Co. Ltd. Glenmark Pharmaceuticals Limited NIRMA Limited Jindal Steel & Power Ltd HCL Infosystems Ltd. Cadila Healthcare Limited Colgate-Palmolive (India) Limited The Great Eastern Shipping Company Limited Aventis Pharma India Ltd Ashok Leyland Limited Pantaloon Retail (India) Limited Indian Rayon And Industries Limited Financial Technologies (India) Ltd United Phosphorus Limited Matrix Laboratories Limited Sesa Goa Limited Lupin Ltd Cummins India Limited Crompton Greaves Limited.
    [Show full text]
  • Market Update
    Market Update April 2021 The markets ended the month of March 2021 with minor gains of 1.1%. Pan-India Covid-19 Forecasted Trends However, the volatility during the month continued to be high. 120000 Concerns of “taper tantrum” and a 2nd wave of Covid-19 cases in 100000 India led to cautiousness and bouts of selloffs. However, economic 80000 indicators and economic recovery enthused investors, leading to 60000 investment interest at every reaction. Broader markets were also 40000 flattish with the BSE Mid-cap and BSE Small-cap 250 indices gaining 1% 20000 and 0.7% respectively. 0 The financial year 2021 turned out to be one of the most eventful year. 02 Mar-20 31 May-21 Starting with Covid-19 related scare and one of the sharpest Daily New Cases Predicted path (27-Oct to 22-Dec) Predicted path (2-Mar to 26-Oct) corrections in recent times, markets ended with a lot of hope, Predicted path (15-Feb to 23-Mar) 7 per, Mov, Avg (Daily Cases) optimism and spectacular gains. Nifty 50 gained a superb 71% for Source: SBI Report FY21, with the broader markets doing much better. The month started on a positive note as after two quarters of Injection to Infection Ratio 7.0 6.1 6.3 6.5 contraction, 3QFY21 GDP grew at 0.4% and vaccination drive gained 6.0 steam. However, the rapid spurt in Covid-19 cases, imposition of 5.0 4.3 3.9 4.0 2.8 lockdowns, night curfews in some parts of India, elevated crude prices 3.0 2.3 2.8 and jump in bond yields weighed on sentiments.
    [Show full text]
  • Model Portfolio Update
    Model Portfolio update September 2, 2016 LatestDeal Team Model – PortfolioAt Your Service Large cap Midcap Name of the company Weightage(%) Name of the company Weightage(%) Auto 15.0 Aviation 6.0 Tata Motor DVR 4.0 Interglobe Aviation 6.0 Bosch 3.0 Auto 6.0 Maruti 5.0 Bharat Forge 6.0 EICHER Motors 3.0 BFSI 6.0 BFSI 25.0 Bajaj Finserve 6.0 HDFC Bank 8.0 Capital Goods 6.0 Axis Bank 3.0 Bharat Electronics 6.0 HDFC 8.0 Cement 6.0 Bajaj Finance 6.0 Ramco Cement 6.0 Capital Goods 4.0 Consumer 30.0 L & T 4.0 Symphony 606.0 Cement 4.0 UltraTech Cement 4.0 Supreme Ind 6.0 FMCG/Consumer 18.0 Kansai Nerolac 6.0 Dabur 5.0 Pidilite 6.0 Marico 4.0 Rallis 6.0 Asian Paints 5.0 Infrastructure 8.0 Nestle 4.0 NBCC 8.0 IT 18. 0 Logistics 606.0 Infosys 10.0 Container Corporation of India 6.0 TCS 8.0 Pharma 20.0 Media 2.0 Natco Pharma 6.0 Zee Entertainment 2.0 Torrent Pharma 6.0 Pharma 14.0 Biocon 8.0 Lupin 6.0 Textile 6.0 DRddDr Reddys 505.0 Arvind 6.0 Aurobindo Pharma 3.0 Total 100.0 Total 100.0 • Exclusion - ITC, Wipro and Reliance Industries • Exclusion – Nestlé shifted to Large cap • Inclusion – Dabur, increased weight in Maruti, Marico, Bajaj Finance & • Inclusion - Biocon UltraTech. Also Nestlé transferred from Midcap to Large cap Source: Bloomberg, ICICIdirect.com Research *Diversified portfolio - Combination of 70% large cap and 30% midcap portfolio OutperformanceDeal Team – At continues Your Service across all portfolios… • Our indicative large cap equity model portfolio has continued to deliver an • In the large cap space, we continue to remain positive on auto, impressive return (inclusive of dividends) of 108.5% since its inception infrastructure & cement.
    [Show full text]
  • Chronic Hepatitis C Treatment Expansion: Generic Manufacturing
    CHRONIC HEPATITIS C TREATMENT EXPANSION Generic Manufacturing for Developing Countries Gilead is working to enable access to its medicines for all people who can benefit from them, regardless of where they live or their economic means. Snapshot Gilead has agreements with 11 There are 103 million Gilead also offers its branded Indian companies to manufacture people living with hepatitis C hepatitis C medicines at a generic hepatitis C medicines for in these developing countries significantly reduced flat 101 developing countries price in these countries For more than a decade, Gilead has been working in partnership with governments, healthcare systems, providers, public health entities and generic manufacturers to make its HIV and hepatitis B medicines available worldwide. Currently, 8 million people living with HIV in developing countries receive Gilead antiretroviral medicines through these efforts. Gilead is now working to help ensure broad access to its hepatitis C medicines in developing countries. Gilead has signed agreements with 11 India-based generic pharmaceutical manufacturers to develop sofosbuvir, the single tablet regimen of ledipasvir/sofosbuvir and the investigational single tablet regimen of sofosbuvir/ velpatasvir for distribution in 101 developing countries. Gilead has also signed agreements with three local generic manufacturers for in-country production and distribution of our hepatitis C medicines in Egypt and Pakistan. Generic Agreements Under the licensing agreements, Gilead’s Indian generic manufacturing partners have the right to develop and market generic versions of Gilead HCV medicines in certain developing countries. The generic drug companies may set their own prices and receive a complete technology transfer of the Gilead manufacturing process, enabling them to scale up production as quickly as possible.
    [Show full text]
  • List of Nodal Officer
    List of Nodal Officer Designa S.No tion of Phone (With Company Name EMAIL_ID_COMPANY FIRST_NAME MIDDLE_NAME LAST_NAME Line I Line II CITY PIN Code EMAIL_ID . Nodal STD/ISD) Officer 1 VIPUL LIMITED [email protected] PUNIT BERIWALA DIRT Vipul TechSquare, Golf Course Road, Sector-43, Gurgaon 122009 01244065500 [email protected] 2 ORIENT PAPER AND INDUSTRIES LTD. [email protected] RAM PRASAD DUTTA CSEC BIRLA BUILDING, 9TH FLOOR, 9/1, R. N. MUKHERJEE ROAD KOLKATA 700001 03340823700 [email protected] COAL INDIA LIMITED, Coal Bhawan, AF-III, 3rd Floor CORE-2,Action Area-1A, 3 COAL INDIA LTD GOVT OF INDIA UNDERTAKING [email protected] MAHADEVAN VISWANATHAN CSEC Rajarhat, Kolkata 700156 03323246526 [email protected] PREMISES NO-04-MAR New Town, MULTI COMMODITY EXCHANGE OF INDIA Exchange Square, Suren Road, 4 [email protected] AJAY PURI CSEC Multi Commodity Exchange of India Limited Mumbai 400093 0226718888 [email protected] LIMITED Chakala, Andheri (East), 5 ECOPLAST LIMITED [email protected] Antony Pius Alapat CSEC Ecoplast Ltd.,4 Magan Mahal 215, Sir M.V. Road, Andheri (E) Mumbai 400069 02226833452 [email protected] 6 ECOPLAST LIMITED [email protected] Antony Pius Alapat CSEC Ecoplast Ltd.,4 Magan Mahal 215, Sir M.V. Road, Andheri (E) Mumbai 400069 02226833452 [email protected] 7 NECTAR LIFE SCIENCES LIMITED [email protected] SUKRITI SAINI CSEC NECTAR LIFESCIENCES LIMITED SCO 38-39, SECTOR 9-D CHANDIGARH 160009 01723047759 [email protected] 8 ECOPLAST LIMITED [email protected] Antony Pius Alapat CSEC Ecoplast Ltd.,4 Magan Mahal 215, Sir M.V. Road, Andheri (E) Mumbai 400069 02226833452 [email protected] 9 SMIFS CAPITAL MARKETS LTD.
    [Show full text]
  • Resisting the Usual. Natco Pharma Limited
    31st ANNUAL REPORT 2013-14 Resisting the usual. Natco Pharma Limited Natco Pharma Limited Natco House, Road No.2, Banjara Hills, Hyderabad 500 034. www.natcopharma.co.in Corporate Information Board of Directors Resisting Shri V.C. Nannapaneni Chairman & Managing Director Shri T V Rao Director – Nominee of Export-Import Bank of India the usual. Shri G.S. Murthy Director Dr. B.S. Bajaj Director Shri Rajeev Nannapaneni Vice Chairman & Chief Executive Officer It would be easy being the Dr. P. Bhaskara Narayana Director & Chief Financial Officer usual pharmaceutical company. Dr. A.K.S. Bhujanga Rao President (R&D and Technical) Shri D.G. Prasad Director Moreover, at Natco Pharma, we (w.e.f. 13th February, 2014) have selected to resist the usual. Shri. Vivek Chhachhi Director (w.e.f 7th January, 2014) Shri Tarun Khanna Alternate Director to Shri Vivek Chhachhi Shri Nitin Jagannath Deshmukh Director (till 28th January, 2014) CS. M. Adinarayana Bankers Company Secretary & Allahabad Bank Vice President (Legal & Corporate Affairs) State Bank of India Corporation Bank Oriental Bank of Commerce YES Bank Ltd. Axis Bank Ltd. Citibank N.A. Auditors Registered Office M/s. Walker, Chandiok & Co. LLP Natco House, Chartered Accountants, Road No.2, Banjara Hills, 7th Floor, Block III, White House Hyderabad 500 033. Kundan Bagh, Begumpet, www.natcopharma.co.in Contents Corporate identity 2 Financial Highlight 4 Chairman’s address 14 Hyderabad 500 016 Corporate Social Responsibility 35 Directors’ Report 38 Forward-looking statements Forward-looking are forward-looking. This document contains statements about expected future events and financial operating results of Natco Pharma Limited , which There is significant By their nature, forward-looking statements require the Company to make assumptions and are subject inherent risks uncertainties.
    [Show full text]
  • Group1 MAY-2020 APPROVED LIST
    Approved Securities List May 2020 Scrip Name ISIN IDFC PREMIER EQUITY FUND PLAN A GROWTH INF194K01391 DSP BLACKROCK MICRO CAP FUND - REGULAR P INF740K01797 KotAk MAhindrA MF - KotAk NV 20 ETF - DP INF174K01Z71 DSP BlAckRock Liquid ETF (Daily Dividend INF740KA1EU7 ICICI PrudentiAl BAnk ETF INF109KC1E27 SBI MUTUAL FUND FOCD EQ FD REGULAR GROWT INF200K01370 ABB IndiA Ltd INE117A01022 AmArA RAjA BAtteries Ltd INE885A01032 Hdfc Ltd INE001A01036 Atul Ltd INE100A01010 Force Motors Ltd INE451A01017 BajAj FinAnce Ltd INE296A01024 Century Textiles & Industries Ltd INE055A01016 BatA IndiA Ltd INE176A01028 BEML Limited INE258A01016 BhArAt Electronics Ltd INE263A01024 Tata Steel Bsl Ltd INE824B01021 Blue StAr Ltd INE472A01039 CESC Ltd INE486A01013 ChAmbAl Fertilisers & ChemicAls Ltd INE085A01013 Exide Industries Ltd INE302A01020 CiplA Ltd INE059A01026 CRISIL Limited INE007A01025 Dabur IndiA Ltd INE016A01026 Arvind Ltd INE034A01011 BhArAt HeAvy ElectricAls Ltd INE257A01026 HindustAn Petroleum CorporAtion Ltd INE094A01015 IFCI Ltd INE039A01010 MangAlore Refinery & PetrochemicAls Ltd INE103A01014 ChennAi Petroleum CorporAtion Ltd INE178A01016 Titan CompAny Ltd INE280A01028 IDBI BAnk Limited INE008A01015 Dr Reddys LAborAtories Ltd INE089A01023 EID PArry IndiA Ltd INE126A01031 PROCTER & GAMBLE HEALTH LIMITED INE199A01012 Uflex Ltd INE516A01017 Godfrey Phillips IndiA Ltd INE260B01028 Godrej Industries Ltd INE233A01035 KansAi NerolAc PAints Ltd INE531A01024 Hdfc BAnk Ltd. INE040A01034 Hero MotoCorp Limited INE158A01026 HimAchAl Futuristic CommunicAtions Ltd
    [Show full text]